

# Theoharis C Theoharides

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3160740/theoharis-c-theoharides-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

9,076  
citations

50  
h-index

92  
g-index

169  
ext. papers

10,518  
ext. citations

5.8  
avg, IF

6.76  
L-index

#	Paper	IF	Citations
148	Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?. <i>Molecular Neurobiology</i> , <b>2022</b> , 59, 1850	6.2	15
147	Need to define a subgroup of patients with idiopathic mast cell activation syndrome.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> , 10, 1127-1128	5.4	2
146	Successful Treatment of a Severe COVID-19 Patient Using an Integrated Approach Addressing Mast Cells and Their Mediators.. <i>International Journal of Infectious Diseases</i> , <b>2022</b> ,	10.5	1
145	Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	3
144	Luteolin: The wonder flavonoid. <i>BioFactors</i> , <b>2021</b> , 47, 139-140	6.1	4
143	Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. <i>BioFactors</i> , <b>2021</b> , 47, 232-241	6.1	33
142	A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
141	Potential association of mast cells with coronavirus disease 2019. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2021</b> , 126, 217-218	3.2	33
140	IL-1B(3954) polymorphism and red complex bacteria increase IL-1[[GCF) levels in periodontitis. <i>Journal of Periodontal Research</i> , <b>2021</b> , 56, 501-511	4.3	4
139	Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. <i>BioFactors</i> , <b>2021</b> , 47, 207-217.	6.1	14
138	Ways to Address Perinatal Mast Cell Activation and Focal Brain Inflammation, including Response to SARS-CoV-2, in Autism Spectrum Disorder. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	4
137	COVID-19, microthromboses, inflammation, and platelet activating factor. <i>BioFactors</i> , <b>2020</b> , 46, 927-933.	6.1	25
136	Effect of Stress on Neuroimmune Processes. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 1007-1014	3.5	13
135	IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 16475-16480	11.5	13
134	Amyotrophic Lateral Sclerosis, Neuroinflammation, and Cromolyn. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 546-549.	3.5	3
133	The impact of psychological stress on mast cells. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 125, 388-392	3.2	19
132	Coronavirus 2019, Microthromboses, and Platelet Activating Factor. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 1850-1852.	3.5	17

131	Increased Expression of miR-155p5 in Amygdala of Children With Autism Spectrum Disorder. <i>Autism Research</i> , <b>2020</b> , 13, 18-23	5.1	10
130	Topical Application of a Mast Cell Stabilizer Improves Impaired Diabetic Wound Healing. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 901-911.e11	4.3	25
129	Substance P and Hemokinin 1 in Nasal Lavage Fluid of Patients with Chronic Sinusitis and Nasal Polyposis. <i>OTO Open</i> , <b>2019</b> , 3, 2473974X19875076	2	2
128	IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 21659-21665	11.5	22
127	Effect of stress on learning and motivation-relevance to autism spectrum disorder. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2019</b> , 33, 2058738419856760	3	7
126	Intimate Contact Could Be Dangerous for Your Health. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 1222-1226	3.5	2
125	IgE and macrophages for cancer rescue?. <i>EBioMedicine</i> , <b>2019</b> , 43, 7-8	8.8	
124	Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 639-656	5.1	46
123	Effects of an Extract of Salmon Milt on Symptoms and Serum TNF and Substance P in Patients With Fibromyalgia Syndrome. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 1564-1574.e2	3.5	1
122	Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. <i>Frontiers in Cellular Neuroscience</i> , <b>2019</b> , 13, 353	6.1	42
121	Mast Cells, Stress, Fear and Autism Spectrum Disorder. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	12
120	Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
119	IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF- $\kappa$ B, inhibited by methoxyluteolin. <i>European Journal of Pharmacology</i> , <b>2019</b> , 865, 172760	5.3	21
118	Nasal cytology with emphasis on mast cells can improve the diagnosis and treatment of chronic rhinosinusitis. <i>Chinese Medical Journal</i> , <b>2019</b> , 132, 2237-2241	2.9	1
117	Mitochondrial dysfunction in affected skin and increased mitochondrial DNA in serum from patients with psoriasis. <i>Experimental Dermatology</i> , <b>2019</b> , 28, 72-75	4	15
116	Effect of IL-33 on de novo synthesized mediators from human mast cells. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 451	11.5	11
115	Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33. <i>BioFactors</i> , <b>2019</b> , 45, 49-61	6.1	13
114	Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. <i>Canadian Journal of Diabetes</i> , <b>2018</b> , 42, 568-573	2.1	14

113	Impact of mast cells in mucosal immunity of intestinal inflammation: Inhibitory effect of IL-37. <i>European Journal of Pharmacology</i> , <b>2018</b> , 818, 294-299	5.3	20
112	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Metabolic Disease or Disturbed Homeostasis due to Focal Inflammation in the Hypothalamus?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2018</b> , 367, 155-167	4.7	19
111	Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. <i>Allergy and Asthma Proceedings</i> , <b>2018</b> , 39, 153-160	2.6	29
110	Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers). <i>Immunologic Research</i> , <b>2018</b> , 66, 323-331	4.3	9
109	Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. <i>Clinical Therapeutics</i> , <b>2018</b> , 40, 903-917	3.5	43
108	Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases. <i>Current Topics in Medicinal Chemistry</i> , <b>2018</b> , 18, 1872-1882	3	11
107	TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. <i>Experimental Dermatology</i> , <b>2018</b> , 27, 135-143	4	25
106	Substance P and IL-33 administered together stimulate a marked secretion of IL-1 $\beta$ from human mast cells, inhibited by methoxyluteolin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E9381-E9390	11.5	46
105	Extracellular vesicles are increased in the serum of children with autism spectrum disorder, contain mitochondrial DNA, and stimulate human microglia to secrete IL-1 $\beta$ . <i>Journal of Neuroinflammation</i> , <b>2018</b> , 15, 239	10.1	50
104	Mast cells participate in allograft rejection: can IL-37 play an inhibitory role?. <i>Inflammation Research</i> , <b>2018</b> , 67, 747-755	7.2	6
103	Neuroendocrinology of mast cells: Challenges and controversies. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 751-759	4	59
102	Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2017</b> , 361, 462-471	4.7	26
101	Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. <i>Tissue and Cell</i> , <b>2017</b> , 49, 393-400	2.7	18
100	Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2017</b> , 30, 146-151	3	16
99	SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E4002-E4009	11.5	81
98	Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. <i>Immunologic Research</i> , <b>2017</b> , 65, 982-986	4.3	9
97	Reply to Fattori et al.: Action of SP and IL-33 on mast cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E10036	11.5	
96	Link between mast cells and bacteria: Antimicrobial defense, function and regulation by cytokines. <i>Medical Hypotheses</i> , <b>2017</b> , 106, 10-14	3.8	13

95	Mast cells, brain inflammation and autism. <i>European Journal of Pharmacology</i> , <b>2016</b> , 778, 96-102	5.3	69
94	Neuroendocrinology of the skin. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2016</b> , 17, 287-294	10.5	27
93	Skin mast cells: are we missing the forest for the trees?. <i>Experimental Dermatology</i> , <b>2016</b> , 25, 422-3	4	11
92	Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 356, 664-72	4.7	59
91	Post-Lyme Syndrome-Associated Polyneuropathy Treated With Immune Immunoglobulin and a Luteolin-Containing Formulation. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 290-1	1.7	2
90	Nanotube Formation: A Rapid Form of "Alarm Signaling"?. <i>Clinical Therapeutics</i> , <b>2016</b> , 38, 1066-72	3.5	13
89	Mast Cells Regulate Wound Healing in Diabetes. <i>Diabetes</i> , <b>2016</b> , 65, 2006-19	0.9	73
88	Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E7049-E7058	11.5	71
87	Mast Cells, Mastocytosis, and Related Disorders. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 163-72	59.2	297
86	Targeting IL-33 in autoimmunity and inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2015</b> , 354, 24-31	4.7	65
85	The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 1044-1052.e5	11.5	85
84	Mast cells promote malaria infection?. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 1374-7	3.5	5
83	Mast Cells, Mastocytosis, and Related Disorders. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1885-6	59.2	32
82	Fibromyalgia syndrome in need of effective treatments. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2015</b> , 355, 255-63	4.7	50
81	Mast cells in meningiomas and brain inflammation. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 170	10.1	40
80	Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. <i>Frontiers in Neuroscience</i> , <b>2015</b> , 9, 225	5.1	68
79	Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 984-95	3.5	325
78	Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders. <i>Journal of Neuroimmunology</i> , <b>2015</b> , 279, 33-8	3.5	40

77	Genitourinary mast cells and survival. <i>Translational Andrology and Urology</i> , <b>2015</b> , 4, 579-86	2.3	7
76	High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 134, 1197-9	11.5	20
75	Stress triggers coronary mast cells leading to cardiac events. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2014</b> , 112, 309-16	3.2	48
74	Trigeminal nerve stimulation triggers oral mast cell activation and vascular permeability. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2014</b> , 112, 40-5	3.2	8
73	A probable case report of stress-induced anaphylaxis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2014</b> , 112, 383-4	3.2	10
72	Exosomes in neurologic and psychiatric disorders. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 882-8	3.5	50
71	Luteolin inhibits human keratinocyte activation and decreases NF- $\kappa$ B induction that is increased in psoriatic skin. <i>PLoS ONE</i> , <b>2014</b> , 9, e90739	3.7	47
70	Isoflavones inhibit poly(I:C)-induced serum, brain, and skin inflammatory mediators - relevance to chronic fatigue syndrome. <i>Journal of Neuroinflammation</i> , <b>2014</b> , 11, 168	10.1	14
69	Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 187-9	1.7	21
68	Focal brain inflammation and autism. <i>Journal of Neuroinflammation</i> , <b>2013</b> , 10, 46	10.1	106
67	The "missing link" in autoimmunity and autism: extracellular mitochondrial components secreted from activated live mast cells. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 1136-42	13.6	35
66	Is a subtype of autism an allergy of the brain?. <i>Clinical Therapeutics</i> , <b>2013</b> , 35, 584-91	3.5	39
65	Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2013</b> , 111, 542-7	3.2	27
64	Luteolin inhibits human cultured keratinocyte inflammatory cytokine release and proliferation. <i>FASEB Journal</i> , <b>2013</b> , 27, lb564	0.9	1
63	Mast cells and inflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2012</b> , 1822, 21-336.9		489
62	Mast cell activation and autism. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2012</b> , 1822, 34-41	6.9	73
61	Perinatal stress, brain inflammation and risk of autism-review and proposal. <i>BMC Pediatrics</i> , <b>2012</b> , 12, 89	2.6	90
60	Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 85	10.1	41

59	Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 1410-3	11.5	42
58	Contribution of stress to asthma worsening through mast cell activation. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2012</b> , 109, 14-9	3.2	47
57	Neurotensin and CRH interactions augment human mast cell activation. <i>PLoS ONE</i> , <b>2012</b> , 7, e48934	3.7	69
56	Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 324-9	4.3	61
55	Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. <i>PLoS ONE</i> , <b>2012</b> , 7, e33805	3.7	111
54	Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. <i>PLoS ONE</i> , <b>2012</b> , 7, e49767	3.7	78
53	Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 1522-31.e8	11.5	101
52	Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. <i>Trends in Pharmacological Sciences</i> , <b>2011</b> , 32, 534-42	13.2	40
51	Neuro-inflammation, blood-brain barrier, seizures and autism. <i>Journal of Neuroinflammation</i> , <b>2011</b> , 8, 168	10.1	67
50	Brief report: "allergic symptoms" in children with Autism Spectrum Disorders. More than meets the eye?. <i>Journal of Autism and Developmental Disorders</i> , <b>2011</b> , 41, 1579-85	4.6	47
49	Umbilical Cord Derived Mast Cells as Models for the Study of Inflammatory Diseases <b>2010</b> , 103-145		
48	Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. <i>International Archives of Allergy and Immunology</i> , <b>2010</b> , 151, 38-45	3.7	34
47	Neurotensin is increased in serum of young children with autistic disorder. <i>Journal of Neuroinflammation</i> , <b>2010</b> , 7, 48	10.1	53
46	Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. <i>Journal of Neuroinflammation</i> , <b>2010</b> , 7, 80	10.1	62
45	IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 4448-53	11.5	225
44	Brain metastases of mouse mammary adenocarcinoma is increased by acute stress. <i>Brain Research</i> , <b>2010</b> , 1366, 204-10	3.7	17
43	IL-32 is increased along with tryptase in lesional psoriatic skin and is up-regulated by substance P in human mast cells. <i>European Journal of Dermatology</i> , <b>2010</b> , 20, 865-7	0.8	31
42	Human mast cell degranulation is distinguished from selective secretion of TNF through intracellular calcium, energy and mitochondrial morphology dynamics. <i>FASEB Journal</i> , <b>2010</b> , 24, 966.3	0.9	

41	Autism: an emerging neuroimmune disorder in search of therapy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 2127-43	4	59
40	Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content. <i>Journal of Immunology</i> , <b>2009</b> , 183, 6313-9	5.3	41
39	Luteolin as a therapeutic option for multiple sclerosis. <i>Journal of Neuroinflammation</i> , <b>2009</b> , 6, 29	10.1	52
38	Autism spectrum disorders and mastocytosis. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2009</b> , 22, 859-65	3	49
37	Impact of stress and mast cells on brain metastases. <i>Journal of Neuroimmunology</i> , <b>2008</b> , 205, 1-7	3.5	46
36	Novel therapeutic targets for autism. <i>Trends in Pharmacological Sciences</i> , <b>2008</b> , 29, 375-82	13.2	48
35	Interstitial cystitis: bladder pain and beyond. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 2979-94	4	32
34	Uncoupling protein 2 regulates mast cell activation. <i>FASEB Journal</i> , <b>2008</b> , 22, 1139.1	0.9	
33	Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2007</b> , 98, 269-73	3.2	26
32	Treatment approaches for painful bladder syndrome/interstitial cystitis. <i>Drugs</i> , <b>2007</b> , 67, 215-35	12.1	36
31	Differential release of mast cell mediators and the pathogenesis of inflammation. <i>Immunological Reviews</i> , <b>2007</b> , 217, 65-78	11.3	314
30	Corticotropin-releasing hormone and the blood-brain-barrier. <i>Frontiers in Bioscience - Landmark</i> , <b>2007</b> , 12, 1615-28	2.8	98
29	Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. <i>Advances in Experimental Medicine and Biology</i> , <b>2007</b> , 601, 423-30	3.6	31
28	Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. <i>Molecular Pharmacology</i> , <b>2006</b> , 69, 998-1006	4.3	66
27	Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 7759-64	11.5	104
26	Neuroimmunoendocrine circuitry of the brain-skin connection. <i>Trends in Immunology</i> , <b>2006</b> , 27, 32-9	14.4	247
25	Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. <i>British Journal of Pharmacology</i> , <b>2006</b> , 148, 208-15	8.6	77
24	The critical role of mast cells in allergy and inflammation. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1088, 78-99	6.5	212



23	Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. <i>British Journal of Pharmacology</i> , <b>2005</b> , 145, 934-44	8.6	221
22	Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. <i>Journal of Immunology</i> , <b>2005</b> , 174, 7665-75	5.3	267
21	Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. <i>Endocrinology</i> , <b>2004</b> , 145, 43-8	4.8	143
20	Critical role of mast cells in inflammatory diseases and the effect of acute stress. <i>Journal of Neuroimmunology</i> , <b>2004</b> , 146, 1-12	3.5	336
19	Mast cells as targets of corticotropin-releasing factor and related peptides. <i>Trends in Pharmacological Sciences</i> , <b>2004</b> , 25, 563-8	13.2	246
18	Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. <i>Cardiovascular Research</i> , <b>2003</b> , 59, 241-9	9.9	65
17	Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. <i>International Archives of Allergy and Immunology</i> , <b>2003</b> , 130, 224-31	3.7	73
16	Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. <i>Brain Research</i> , <b>2003</b> , 980, 213-20	3.7	58
15	The Effect of a Herbal Water-Extract on Histamine Release from Mast Cells and on Allergic Asthma. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , <b>2003</b> , 3, 41-54		29
14	IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. <i>Journal of Immunology</i> , <b>2003</b> , 171, 4830-6	5.3	175
13	Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 1061-6	4.7	191
12	Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. <i>International Archives of Allergy and Immunology</i> , <b>2002</b> , 128, 344-50	3.7	77
11	PENTOSANPOLYSULFATE INHIBITS MAST CELL HISTAMINE SECRETION AND INTRACELLULAR CALCIUM ION LEVELS:: AN ALTERNATIVE EXPLANATION OF ITS BENEFICIAL EFFECT IN INTERSTITIAL CYSTITIS. <i>Journal of Urology</i> , <b>2000</b> , 164, 2119-2125	2.5	62
10	Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. <i>Brain Research</i> , <b>1999</b> , 849, 1-15	3.7	169
9	Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: A link to neurogenic skin disorders. <i>Brain, Behavior, and Immunity</i> , <b>1999</b> , 13, 225-39	16.6	276
8	Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 798-803	4.5	24
7	Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. <i>Endocrinology</i> , <b>1998</b> , 139, 403-13	4.8	354
6	Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. <i>FASEB Journal</i> , <b>1998</b> , 12, 1693-700	0.9	68

5	Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>1997</b> , 31, 497-500		7
4	Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells. <i>Molecular and Cellular Biochemistry</i> , <b>1996</b> , 155, 61-8	4.2	7
3	Inhibition of mast cell secretion by oxidation products of natural polyamines. <i>Biochemical Pharmacology</i> , <b>1992</b> , 43, 2237-45	6	22
2	Histamine <sub>2</sub> (H <sub>2</sub> )-receptor antagonists in the treatment of urticaria. <i>Drugs</i> , <b>1989</b> , 37, 345-55	12.1	23
1	The Effect of a Herbal Water-Extract on Histamine Release from Mast Cells and on Allergic Asthma		3